NASDAQ:XFOR X4 Pharmaceuticals (XFOR) Stock Forecast, Price & News $2.20 +0.17 (+8.37%) (As of 11:10 AM ET) Add Compare Share Share Today's Range$2.00▼$2.2250-Day Range$0.80▼$2.2052-Week Range$0.65▼$2.41Volume1.64 million shsAverage Volume2.14 million shsMarket Capitalization$268.86 millionP/E RatioN/ADividend YieldN/APrice Target$3.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability X4 Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside72.4% Upside$3.50 Price TargetShort InterestHealthy2.41% of Shares Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment0.84Based on 2 Articles This WeekInsider TradingSelling Shares$12,269 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.63) to ($0.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.52 out of 5 starsMedical Sector197th out of 1,006 stocksBiological Products, Except Diagnostic Industry28th out of 167 stocks 3.5 Analyst's Opinion Consensus RatingX4 Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.50, X4 Pharmaceuticals has a forecasted upside of 72.4% from its current price of $2.03.Amount of Analyst CoverageX4 Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted2.41% of the outstanding shares of X4 Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverX4 Pharmaceuticals has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in X4 Pharmaceuticals has recently decreased by 2.64%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldX4 Pharmaceuticals does not currently pay a dividend.Dividend GrowthX4 Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreX4 Pharmaceuticals has received a 71.51% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for mental health" and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for X4 Pharmaceuticals is -0.85. Previous Next 3.2 News and Social Media Coverage News SentimentX4 Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for X4 Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest44 people have searched for XFOR on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.MarketBeat Follows7 people have added X4 Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, X4 Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,269.00 in company stock.Percentage Held by InsidersOnly 1.08% of the stock of X4 Pharmaceuticals is held by insiders.Percentage Held by Institutions56.46% of the stock of X4 Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for X4 Pharmaceuticals are expected to grow in the coming year, from ($0.63) to ($0.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of X4 Pharmaceuticals is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of X4 Pharmaceuticals is -1.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioX4 Pharmaceuticals has a P/B Ratio of 4.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About X4 Pharmaceuticals (NASDAQ:XFOR) StockX4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.Read More Receive XFOR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for X4 Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address XFOR Stock News HeadlinesMay 25, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)May 24, 2023 | americanbankingnews.comFY2023 EPS Estimates for X4 Pharmaceuticals, Inc. Lifted by Analyst (NASDAQ:XFOR)June 1, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 23, 2023 | americanbankingnews.comB. Riley Analysts Raise Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)May 20, 2023 | americanbankingnews.comStifel Nicolaus Boosts X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $5.00May 20, 2023 | americanbankingnews.comFY2026 EPS Estimates for X4 Pharmaceuticals, Inc. Lowered by Analyst (NASDAQ:XFOR)May 19, 2023 | americanbankingnews.comBrookline Capital Management Analysts Raise Earnings Estimates for X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)May 17, 2023 | msn.comStifel Maintains X4 Pharmaceuticals (XFOR) Buy RecommendationJune 1, 2023 | Edge On The Street (Ad)Graphite versus Lithium - What Investors Should KnowOver 18 million EVs will be cruising U.S roads by 2030. And every one million EVs manufactured will require 82,000 tons of the metal graphite for their batteries. That's a total of 1,476,000 tons of graphite! Graphite is actually the largest component of EV batteries - NOT lithium. Experts warn of a massive graphite shortfall, especially since North America currently has no operating graphite mines.May 17, 2023 | msn.comUnusual Call Option Trade in X4 Pharmaceuticals (XFOR) Worth $24.36KMay 17, 2023 | msn.comX4 Pharma Highlights 'Significant Reduction' Rate In Severity, Duration Of InfectionsMay 16, 2023 | finance.yahoo.comX4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM SyndromeMay 16, 2023 | finance.yahoo.comX4 Pharmaceuticals Announces $65 Million Private Placement Priced At-the-MarketMay 10, 2023 | americanbankingnews.comAnalysts Set Expectations for X4 Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:XFOR)May 6, 2023 | americanbankingnews.comOpthea (NASDAQ:OPT) versus X4 Pharmaceuticals (NASDAQ:XFOR) Critical ContrastMay 5, 2023 | markets.businessinsider.comWhat 5 Analyst Ratings Have To Say About X4 PharmaceuticalsMay 5, 2023 | msn.comHC Wainwright & Co. Reiterates X4 Pharmaceuticals (XFOR) Buy RecommendationMay 4, 2023 | msn.comX4 Pharmaceuticals: Q1 Earnings InsightsMay 4, 2023 | finance.yahoo.comX4 Pharmaceuticals Reports First-Quarter 2023 Financial Results and Provides Corporate UpdateApril 29, 2023 | americanbankingnews.comX4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Short Interest Up 86.8% in AprilApril 26, 2023 | finance.yahoo.comX4 Pharmaceuticals to Report First-Quarter 2023 Financial Results and Host a Conference Call and Webcast on May 4, 2023April 26, 2023 | finance.yahoo.comX4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) largest shareholders are retail investors with 42% ownership, institutions own 32%April 12, 2023 | finance.yahoo.comX4 Pharmaceuticals Announces Late-Breaking Abstract of WHIM Phase 3 Clinical Data Accepted for Oral Presentation at the 2023 Annual Meeting of the Clinical Immunology Society (CIS)April 12, 2023 | americanbankingnews.comX4 Pharmaceuticals (NASDAQ:XFOR) Given New $3.00 Price Target at B. RileyApril 10, 2023 | msn.comB. Riley Securities Maintains X4 Pharmaceuticals (XFOR) Buy RecommendationApril 6, 2023 | markets.businessinsider.comB.Riley Financial Keeps Their Buy Rating on X4 Pharmaceuticals (XFOR)April 4, 2023 | finance.yahoo.comX4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)See More Headlines XFOR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart XFOR Company Calendar Last Earnings3/21/2023Today6/01/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XFOR CUSIPN/A CIK1501697 Webwww.x4pharma.com Phone(857) 529-8300FaxN/AEmployees83Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.50 High Stock Price Forecast$5.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+72.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,870,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-176.29% Return on Assets-80.88% Debt Debt-to-Equity Ratio0.62 Current Ratio5.04 Quick Ratio5.04 Sales & Book Value Annual Sales$3 million Price / Sales82.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.42 per share Price / Book4.83Miscellaneous Outstanding Shares122,210,000Free Float120,887,000Market Cap$248.09 million OptionableNot Optionable Beta0.70 Key ExecutivesPaula S. RaganPresident, Chief Executive Officer & DirectorMary DiBiaseChief Operating OfficerAdam S. MostafaChief Financial Officer & TreasurerMurray Willis StewartIndependent Director & Chief Medical OfficerArt TaverasChief Scientific OfficerKey CompetitorsMolecular PartnersNASDAQ:MOLNInnate PharmaNASDAQ:IPHASangamo TherapeuticsNASDAQ:SGMOPoseida TherapeuticsNASDAQ:PSTXIkena OncologyNASDAQ:IKNAView All CompetitorsInsiders & InstitutionsPaula RaganSold 6,292 sharesTotal: $12,269.40 ($1.95/share)JPMorgan Chase & Co.Bought 506,449 shares on 5/18/2023Ownership: 0.512%Perceptive Advisors LLCBought 4,545,454 shares on 5/16/2023Ownership: 3.719%Geode Capital Management LLCBought 521,168 shares on 5/16/2023Ownership: 0.907%Susquehanna International Group LLPSold 3,700 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions XFOR Stock - Frequently Asked Questions Should I buy or sell X4 Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for X4 Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" XFOR shares. View XFOR analyst ratings or view top-rated stocks. What is X4 Pharmaceuticals' stock price forecast for 2023? 5 brokerages have issued 1 year price targets for X4 Pharmaceuticals' shares. Their XFOR share price forecasts range from $3.00 to $5.00. On average, they anticipate the company's share price to reach $3.50 in the next twelve months. This suggests a possible upside of 72.4% from the stock's current price. View analysts price targets for XFOR or view top-rated stocks among Wall Street analysts. How have XFOR shares performed in 2023? X4 Pharmaceuticals' stock was trading at $0.9930 at the start of the year. Since then, XFOR shares have increased by 104.4% and is now trading at $2.03. View the best growth stocks for 2023 here. When is X4 Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our XFOR earnings forecast. How were X4 Pharmaceuticals' earnings last quarter? X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) issued its quarterly earnings results on Tuesday, March, 21st. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.06. What ETFs hold X4 Pharmaceuticals' stock? ETFs with the largest weight of X4 Pharmaceuticals (NASDAQ:XFOR) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS) and Simplify Propel Opportunities ETF (SURI) and What other stocks do shareholders of X4 Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other X4 Pharmaceuticals investors own include Dynavax Technologies (DVAX), Ovid Therapeutics (OVID), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), AbbVie (ABBV), Flexion Therapeutics (FLXN), Heat Biologics (HTBX) and SCYNEXIS (SCYX). What is X4 Pharmaceuticals' stock symbol? X4 Pharmaceuticals trades on the NASDAQ under the ticker symbol "XFOR." Who are X4 Pharmaceuticals' major shareholders? X4 Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (3.72%), AXA S.A. (3.60%), Geode Capital Management LLC (0.91%), Schonfeld Strategic Advisors LLC (0.85%), Ghost Tree Capital LLC (0.70%) and JPMorgan Chase & Co. (0.51%). Insiders that own company stock include Adam S Mostafa, Adam S Mostafa, Arthur Taveras, Derek M Meisner, Derek M Meisner, Mary Dibiase, Paula Ragan and Renato Skerlj. View institutional ownership trends. How do I buy shares of X4 Pharmaceuticals? Shares of XFOR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is X4 Pharmaceuticals' stock price today? One share of XFOR stock can currently be purchased for approximately $2.03. How much money does X4 Pharmaceuticals make? X4 Pharmaceuticals (NASDAQ:XFOR) has a market capitalization of $248.09 million and generates $3 million in revenue each year. The company earns $-93,870,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis. How can I contact X4 Pharmaceuticals? X4 Pharmaceuticals' mailing address is 955 Massachusetts Avenue 4th Floor, Cambridge MA, 02139. The official website for the company is www.x4pharma.com. The company can be reached via phone at (857) 529-8300 or via email at ir@arsanis.com. This page (NASDAQ:XFOR) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding X4 Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.